Amiodarona y COVID-19: una llamada de alerta
Texto completo:
PDFPalabras clave
Referencias
Wolkove N, Baltzan M, . Amiodarone pulmonary toxicity. Can Respir J 2009;16(2):43-8.
Terzo F, Ricci A, DAscanio M, Raffa S, Mariotta S. Amiodarone-induced pulmonary toxicity with an excellent response to treatment: a case report. Respiratory Medicine Case reports 2020;100974 https://doi.org/1016/
Wolkove N, Baltzan M.Amiodarone pulmonary toxicity. Can Respir J 2009;16(2):43-8.
Aimo A, Baritussio A, Emdin M, Tascini C. Amiodarone as a possible therapy for coronavirus infection. European Journal of Preventive Cardiology 2020. DOI:10.1177/2047487320919233.
Stadler K, Ha HR, Ciminale V, Spirli C, Saletti G, Schiavon M et al. Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. Am J Respir Cell Mol Biol 2008;39:142-9.
Castaldo N,Aimo A, Castiglione V, Padalino C, Emdin M, Tascini C.Safety and efficacy of amiodarone in a patient with COVID-19. JACC Case Reports 2020 doi.org/10.1016/j.jaccs.2020.04.053.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 7 II 2020. doi:10.1001/jama.2020.1585.
Dvall J, Johnson JC, Hart BJ, Postnikova E, Cong Y, Zhou H et al. In vitro and in vivo activity of amiodarone against Ebola virus. J Infect Dis 2018;S5:S592-6.
.
Enlaces refback
- No hay ningún enlace refback.
Copyright (c) 2020 Margarita Dorantes Sánchez, Marleny Cruz Cardentey, OsmÃn Castañeda Chirino
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.